Kailera Therapeutics, Inc.

424B4 priced

Price $16.00 · 39,062,500 shares · Gross proceeds $625,000,000

Kailera Therapeutics, Inc. is conducting its initial public offering (IPO) of 39,062,500 shares of common stock at $16.00 per share, raising $625 million. The shares are listed on the Nasdaq Global Select Market under 'KLRA.' The company, an emerging growth company, faces risks including clinical trial uncertainties and regulatory approvals. The underwriters include J.P. Morgan, Jefferies, and others, with a 30-day option to purchase additional shares. Existing stockholders may buy up to $225 million in shares, though these are non-binding.

EFFECT effective

Kailera Therapeutics, Inc. has filed an S-1 registration statement, which has been declared effective by the SEC as of April 16, 2026. The filing indicates the company is proceeding with its IPO, though specific details about the offering, financials, or business operations are not visible in the provided text.

CERT inactive

The current filing is a CERT form for Kailera Therapeutics, Inc., submitted on 2026-04-15, following a previous 8-A12B filing. The 8-A12B referenced registration of common stock under Section 12(b) of the Securities Exchange Act, with details incorporated from an S-1 registration statement. The current CERT filing appears to lack readable content, potentially indicating a technical issue or incomplete submission.

8-A12B effective

Kailera Therapeutics, Inc. filed Form 8-A12B to register its common stock for listing on Nasdaq, referencing the previously filed S-1/A registration statement. The current filing focuses on the procedural registration of securities under Section 12(b) of the Exchange Act, incorporating by reference the prospectus details from the S-1/A, which outlined the company's initial public offering (IPO) terms, including share pricing, underwriters, and risk factors.

S-1/A amended

Range $14.00 to $16.00 · 33,333,334 shares

Kailera Therapeutics, Inc. is conducting an initial public offering (IPO) for 33,333,334 shares of common stock, with an expected price range of $14.00 to $16.00 per share. The company, an emerging growth company, focuses on developing obesity management therapies through a diversified pipeline of clinical-stage product candidates, including ribupatide and other GLP-1/GIP receptor agonists. The IPO aims to list on the Nasdaq Global Select Market under the symbol 'KLRA,' contingent on meeting listing standards. The offering includes underwriter options for additional shares and non-binding interest from existing stockholders for up to $225 million in purchases.

S-1 filed

Kailera Therapeutics, Inc. is conducting its initial public offering (IPO) by selling common stock, aiming to list on the Nasdaq Global Select Market under 'KLRA.' The company is a biotechnology firm focused on obesity treatment with a pipeline of four clinical-stage product candidates leveraging GLP-1-based mechanisms. The offering includes details on underwriting, risk factors, and financial disclosures, with the company classified as an emerging growth company and smaller reporting company.

DRS/A amended

Kailera Therapeutics, Inc. filed an amended registration statement (DRS/A) for its initial public offering (IPO) of common stock. The filing updates details about the IPO pricing range, underwriters, and pipeline advancements. The company aims to list on the Nasdaq Global Select Market under the symbol 'KLRA' and emphasizes its GLP-1-based obesity treatment candidates, including ribupatide and KAI-4729. The filing highlights risks related to clinical trial outcomes, regulatory approvals, and market competition.

DRS filed

Kailera Therapeutics, Inc. is conducting its initial public offering (IPO) through a confidential DRS filing, aiming to list on Nasdaq under the symbol 'KLRA.' The company is a clinical-stage biotechnology firm focused on developing obesity treatments, with multiple GLP-1-based product candidates in advanced trials. The filing highlights its emerging growth company status, reduced disclosure requirements, and plans to amend the registration statement to include omitted financial statements before the prospectus is distributed.